MMP-14 (MT1-MMP) Is a Biomarker of Surgical Outcome and a Potential Mediator of Hearing Loss in Patients With Vestibular Schwannomas
Improved biomarkers are needed for vestibular schwannoma (VS), the most common tumor of the cerebellopontine angle, as existing clinical biomarkers have poor predictive value. Factors such as tumor size or growth rate do not shed light on the pathophysiology of associated sensorineural hearing loss...
Main Authors: | Yin Ren, Hiroshi Hyakusoku, Jessica E. Sagers, Lukas D. Landegger, D. Bradley Welling, Konstantina M. Stankovic |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-07-01
|
Series: | Frontiers in Cellular Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fncel.2020.00191/full |
Similar Items
-
Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma
by: Jessica E. Sagers, et al.
Published: (2018-04-01) -
Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas
by: Sagers, Jessica E., et al.
Published: (2018) -
Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas
by: Yin Ren, et al.
Published: (2017-10-01) -
miR-431 secreted by human vestibular schwannomas increases the mammalian inner ear’s vulnerability to noise trauma
by: Takeshi Fujita, et al.
Published: (2023-10-01) -
Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular Schwannoma
by: Samuel Early, et al.
Published: (2020-08-01)